Efecto de la toxina botulínica tipo A en la funcionalidad, las sincinesias y la calidad de vida en secuelas de parálisis facial periférica / Effect of botulinum toxin type A in functionality, synkinesis and quality of life in peripheral facial palsy sequelae

Objetivo: Valorar el efecto del tratamiento con infiltraciones de toxina botulínica tipo A (TXB-A) en la funcionalidad facial, las sincinesias y la calidad de vida en pacientes con secuelas de parálisis facial periférica (PFP). Material y métodos: Presentamos un estudio prospectivo con una muestra de 20 pacientes con secuelas de PFP (15 mujeres, 5 varones) a los que se infiltró TXB-A (Botox® o Xeomin®). Todos los pacientes realizaron previamente un tratamiento personalizado basado en la reeducación neuromuscular. Se realizó una evaluación clínica previa a las infiltraciones y otra al cabo de 4 semanas. El efecto de las infiltraciones sobre la funcionalidad facial fue valorado mediante la escala Sunnybrook Facial Grading System (SFGS); el efecto sobre la calidad de vida se evaluó a través del cuestionario Facial Clinimetric Evaluation Scale (FaCE), y el efecto sobre la reducción de sincinesias se estudió utilizando el Synkinesis Assessment Questionnaire (SAQ). Resultados: La media de los valores del SFGS se incrementó tras el tratamiento con TXB-A, de 64,8 a 69,9 (p = 0,004). También se incrementó la media de los valores del FaCE Total, de 52,42 a 64,5 (p < 0,001), y la media de la subescala Social del FaCE, de 61,15 a 78,44 (p < 0,001). La media de los valores del SAQ disminuyó con las infiltraciones de TXB-A, de 46,22 a 37,55 (p = 0,001). Conclusiones: Las infiltraciones de TXB-A incrementan la funcionalidad facial, mejoran la calidad de vida y reducen las sincinesias en pacientes con secuelas de PFP.(AU)

Objectives: This study aimed to assess the effects of botulinum toxin A (BTX-A) infiltration on face muscle function, synkinesis, and quality of life in patients with sequelae of peripheral facial palsy (PFP). Material and methods: We present the results of a prospective study including a sample of 20 patients with sequelae of PFP (15 women, 5 men) who underwent BTX-A (Botox® or Xeomin®) infiltration. All patients had previously received personalised treatment with neuromuscular retraining. A clinical assessment was performed before BTX-A infiltration and 4 weeks after treatment. The effect of BTX-A on face muscle function, quality of life, and synkinesis was evaluated using the Sunnybrook Facial Grading System (SFGS), the Facial Clinimetric Evaluation (FaCE) questionnaire, and the Synkinesis Assessment Questionnaire (SAQ), respectively. Results: Mean SFGS scores increased from 64.8 to 69.9 after BTX-A infiltration (P = .004). Increases were also observed in mean total FaCE scores (from 52.42 to 64.5; P < .001) and the mean score on the FaCE social function subscale (from 61.15 to 78.44; P < .001). Mean SAQ scores decreased from 46.22 to 37.55 after BTX-A infiltration (P = .001). Conclusions: BTX-A infiltration increases face muscle function, improves quality of life, and reduces synkinesis in patients with sequelae of PFP.(AU)

Effect of botulinum toxin type A in functionality, synkinesis and quality of life in peripheral facial palsy sequelae.

OBJECTIVES: This study aimed to assess the effects of botulinum toxin A (BTX-A) infiltration on face muscle function, synkinesis, and quality of life in patients with sequelae of peripheral facial palsy (PFP). MATERIAL AND METHODS: We present the results of a prospective study including a sample of 20 patients with sequelae of PFP (15 women, 5 men) who underwent BTX-A (Botox© or Xeomin©) infiltration. All patients had previously received personalised treatment with neuromuscular retraining. A clinical assessment was performed before BTX-A infiltration and 4 weeks after treatment. The effect of BTX-A on face muscle function, quality of life, and synkinesis was evaluated using the Sunnybrook Facial Grading System (SFGS), the Facial Clinimetric Evaluation (FaCE) questionnaire, and the Synkinesis Assessment Questionnaire (SAQ), respectively. RESULTS: Mean SFGS scores increased from 64.8 to 69.9 after BTX-A infiltration (P=.004). Increases were also observed in mean total FaCE scores (from 52.42 to 64.5; P<.001) and the mean score on the FaCE social function subscale (from 61.15 to 78.44; P<.001). Mean SAQ scores decreased from 46.22 to 37.55 after BTX-A infiltration (P=.001). CONCLUSIONS: BTX-A infiltration increases face muscle function, improves quality of life, and reduces synkinesis in patients with sequelae of PFP.

Diferencias en la calidad de vida de pacientes con disfagia orofaríngea según el lugar de residencia: impacto en la selección de alimentos y el tipo de dieta / Differences in the quality of life of patients with oropharyngeal dysphagia according to the place of residence: impact on food selection and type of diet

Introducción: la disfagia es un síntoma invalidante, incómodo, con repercusiones en aspectos básicos del bienestar. El test SWAL-QoL esta validado para comprobar el impacto de la disfagia en la calidad de vida (QoL). Métodos: estudio descriptivo transversal (enero 2018). Pacientes con tratamiento de espesante aleatorizados a partir de la base de datos interna de la Unidad de Nutrición y Dietética. Entrevistas telefónicas al paciente o cuidador. Test SWAL-QoL, 11 secciones: carga de enfermedad, síntomas, selección de alimentos, apetito, duración comidas, miedos, comunicación, salud mental, sueño/descanso, fatiga y afectación social. Puntuación ajustada con escala Likert (1-5). Resultados finales transferidos linealmente de 0 a 100 (mejor puntuación positiva). Interpretación: 0-49, impacto severo (IS); 50-70, impacto moderado (IM); y 71-100, impacto discreto o sin impacto (ID/NI). Variables: sexo, edad, días de tratamiento, vivienda en domicilio (D)/residencia(R); indicación de espesante comercial (EC) con MECV-V: néctar (N), miel (M), pudín (P); días con EC, tipo de dieta: puré (DP), blanda (SD), mixta (DM), normal (DN); secciones SWAL-QoL. Resultados: en total, 202 pacientes de 85 años (23-103); IQR: 12. Mayoría de mujeres, 57,9 %; 43,1 % D/56,9 % R. SWAL-QoL: 19,3 % IS, 59,9 % IM y 20,8 % ID/NI. Usar menos espesante demostró mejor QoL, IS en pudín: 21,1 % vs. Néctar: 15,3 %, p = 0,04. Las dietas realizadas fueron: 66,3 % DP; 3 % DB; DM 21,3 %, y DN 9,4 %. En R, más DP (86,1 %) que en D (40,2 %), p < 0,001. DP asociada a peor QoL: % de ID o no impacto en DP, 15,7 % vs. 30,8 % en el resto de dietas, p = 0,016. Analizando cada sección por D/R, diferencia significativa entre miedos, mayor en D (57,01 ± 36,41) vs. R (48,70 ± 27,03), p < 0,001; peor salud mental en R: 66,44 ± 34,30 vs. D: 47,48 ± 24,06, p < 0,001; mejor selección de alimentos en D (75,86 ± 34,12) vs. R (68,17 ± 33,60), p < 0,01 (AU)

Background: dysphagia is a disabling, uncomfortable symptom with repercussions on daily basic aspects of well-being. The SWAL-QoL test is validated for checking dysphagia's impact on quality of life (QoL). Methods: a descriptive cross-sectional study. Randomized patients from our in-house Nutrition & Dietetics database. Telephone interviews directly with patients or caregivers. SWAL-QoL test, 11 sections: swallowing, eating, symptoms, food selection, communication, fears, mental health, fatigue, and social function. A 1-5 Likert scale was adjusted and final results were linearly transferred to 0-100 (100 being best positive score). Results as follows: 0-49 severe impact (SI), 50-70 moderate impact (MI), and 71-100 mild impact or no impact (DI/NI). Variables: gender, age, days with treatment, residence: Home (H)/nursing home (NH), indication of commercial thickener (CT) by V/V test: nectar (N), honey (H), pudding (P), days with CT, type of diets; pureed (PD), soft diet (SD), mixed(P&S/D), regular (RD), SWAL-QoL sections. Results: a total of 202 patients with a mean age of 85 years (23-103); IQR: 12. Mostly women, 57.9 %. Dwelling: 43.1 % H/56.9 % NH. SWAL-QoL: SI affects 19.3 %, 59.9 % MI and 20.8 % DI/NI. Using less thickener proved a better QoL; SI in pudding 21.1 % vs nectar 15.3 %, p = 0.04. Diets included 66.3 % PD; 3 % SD; MD, 21.3 %, and RD, 9.4 %. At NH 86.1 % of PD vs 40.2 % at H, p < 0.001. Direct impact of diet on QoL: 30.8 % on DI or no impact of grouped diets vs 15.7 % with PD, p = 0.016. Analysing each section by H/NH, significant difference between fears, higher at H, 57.01 ± 36.41 vs NH, 48.70 ± 27.03, p < 0.001; worse mental health for NH, 66.44 ± 34.30 vs H, 47.48 ± 24.06, p < 0.001; better food selection for H, 75.86 ± 34.12 vs NH, 68.17 ± 33.60, p < 0.01 (AU)

Effect of botulinum toxin typeA in functionality, synkinesis and quality of life in peripheral facial palsy sequelae. / Efecto de la toxina botulínica tipoA en la funcionalidad, las sincinesias y la calidad de vida en secuelas de parálisis facial periférica.

OBJECTIVES: This study aimed to assess the effects of botulinum toxin A (BTX-A) infiltration on face muscle function, synkinesis, and quality of life in patients with sequelae of peripheral facial palsy (PFP). MATERIAL AND METHODS: We present the results of a prospective study including a sample of 20 patients with sequelae of PFP (15 women, 5 men) who underwent BTX-A (Botox® or Xeomin®) infiltration. All patients had previously received personalised treatment with neuromuscular retraining. A clinical assessment was performed before BTX-A infiltration and 4weeks after treatment. The effect of BTX-A on face muscle function, quality of life, and synkinesis was evaluated using the Sunnybrook Facial Grading System (SFGS), the Facial Clinimetric Evaluation (FaCE) questionnaire, and the Synkinesis Assessment Questionnaire (SAQ), respectively. RESULTS: Mean SFGS scores increased from 64.8 to 69.9 after BTX-A infiltration (P=.004). Increases were also observed in mean total FaCE scores (from 52.42 to 64.5; P<.001) and the mean score on the FaCE social function subscale (from 61.15 to 78.44; P<.001). Mean SAQ scores decreased from 46.22 to 37.55 after BTX-A infiltration (P=.001). CONCLUSIONS: BTX-A infiltration increases face muscle function, improves quality of life, and reduces synkinesis in patients with sequelae of PFP.

Atención farmacéutica en pacientes ingresados con insuficiencia renal / Pharmaceutical care in renal insufficiency inpatients

Objetivos: Valorar los resultados de un programa de ajuste posológico en pacientes hospitalizados con enfermedad renal, describir los medicamentos mayoritariamente implicados y determinar el grado de aceptación de la intervención farmacéutica realizada. Método: Estudio prospectivo, de intervención no aleatorizada, de 15 meses de duración en pacientes hospitalizados con función renal alterada (Creatinina sérica > 1,4 mg/dL) y en tratamiento con medicamentos que precisan ajuste en insuficiencia renal. La variable principal fue el porcentaje de adecuación posológica según la tasa de filtrado glomerular. También se evaluó la aceptación global por servicio clínico, el grupo farmacoterapéutico más prescrito de forma inadecuada, las monitorizaciones farmacocinéticas que se derivaron de la intervención y el carácter educativo de la misma. Resultados: Se identificaron un total de 384 pacientes de los que 341 presentaban un aclaramiento de creatinina entre 10-50 ml/min. Se revisaron 2.807 medicamentos prescritos, de éstos, 2.052 no requerían ajuste posológico en insuficiencia renal y 508 estaban correctamente ajustados. 247 prescripciones eran susceptibles de un ajuste posológico de las cuales 164 prescripciones era necesario un ajuste posológico concreto. Se realizaron recomendaciones posológicas en 200 ocasiones, y se aceptaron un total de 131. Los fármacos con mayor número de intervenciones fueron la enoxaparina, levofloxacino, amoxicilina-clavulánico y digoxina. Conclusiones: La implantación del programa de atención farmacéutica ha tenido una buena aceptación entre los facultativos prescriptores, siendo los antibióticos el grupo farmacológico más susceptible de realizar un ajuste posológico sobre una mayoría de pacientes con insuficiencia renal moderada (AU)

Background and objective: To asses the outcomes of posological adjust program in renal impairment inpatients, describe the drugs more usually involved, and determine the degree of acceptance of the pharmaceutical intervention made. Material and method: A fifteen months-prospective study, in renal insufficiency inpatients (serum creatinine > 1,4 mg/dL) treated with drugs that needs posological adjustment. The primary outcome was the ratio of adequate dosage of the treatment, according with the glomerular filtration rate. We also evaluated the global acceptation rate, the drugs inadequate prescribed more frequently, phamacokinetic analysis derived from the pharmaceutical intervention and its educative character. Results: 384 patients were identified, and 341 of them presented a glomerular filtration rate between 10-50 ml/min. 2.807 prescribed drugs were reviewed, and 2.052 of them didn’t require posological adjustment in renal insufficiency, 508 prescribed drugs were correctly adjusted. 247 pres - criptions were susceptible of posological adjustment and 164 of them, needed a concrete posological adjustment. We performed 200 posological recommendations, and 131 were accepted. The drugs with a higher number of interventions were enoxaparine, levofloxacin, amoxicillin-clavulanic and digoxin. Conclusions: The implementation of the pharmaceutical care program was accepted between physicians, being antibiotics the group more susceptible of doing a posological adjustment in most patients with renal impairment (AU)

[Pharmaceutical care in renal insufficiency inpatients]. / Atención farmacéutica en pacientes ingresados con insuficiencia renal.

BACKGROUND AND OBJECTIVE: To asses the outcomes of posological adjust program in renal impairment inpatients, describe the drugs more usually involved, and determine the degree of acceptance of the pharmaceutical intervention made. MATERIAL AND METHOD: A fifteen months-prospective study, in renal insufficiency inpatients (serum creatinine > 1,4 mg/dL) treated with drugs that needs posological adjustment. The primary outcome was the ratio of adequate dosage of the treatment, according with the glomerular filtration rate. We also evaluated the global acceptation rate, the drugs inadequate prescribed more frequently, phamacokinetic analysis derived from the pharmaceutical intervention and its educative character. RESULTS: 384 patients were identified, and 341 of them presented a glomerular filtration rate between 10-50 ml/min. 2.807 prescribed drugs were reviewed, and 2.052 of them didn%#39;t require posological adjustment in renal insufficiency, 508 prescribed drugs were correctly adjusted. 247 pres - criptions were susceptible of posological adjustment and 164 of them, needed a concrete posological adjustment. We performed 200 posological recommendations, and 131 were accepted. The drugs with a higher number of interventions were enoxaparine, levofloxacin, amoxicillin-clavulanic and digoxin. CONCLUSIONS: The implementation of the pharmaceutical care program was accepted between physicians, being antibiotics the group more susceptible of doing a posological adjustment in most patients with renal impairment.

[Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome: a well-defined clinical condition with a heterogeneous immunological profile]. / Variante faringocervicobraquial del síndrome de Guillain-Barré: una entidad clínica bien definida con un perfil inmunológico heterogéneo.

INTRODUCTION: The pharyngeal-cervical-brachial variant of Guillain-Barre syndrome (GBS) is rare. This variant has its own specific clinical aspects but a heterogeneous immunological profile. CASE REPORT: A 38-year-old male who presented progressive symptoms of dysphagia, dysphonia and weakness hindering movement of the upper limbs. Two weeks earlier, the patient had presented acute self-limiting diarrhoea. He displayed predominantly right-side bilateral peripheral facial paresis, and paresis of the 9th and 12th cranial nerves and upper limbs (proximal 0/5, distal 1/5), although strength in the lower limbs was not compromised; sensitivity was preserved and deep tendon reflexes were diminished (0 in the upper limbs and + in the lower extremities). At 24 hours after admission, he suffered severe respiratory distress and had to be moved to the Intensive Care Unit with invasive mechanical ventilation. An electronystagmography/electromyogram study revealed severe demyelinating damage that predominantly involved the brain, but also included a small axonal component. The most striking immunological finding was the presence of positive IgG anti-GQ1b, IgM anti-GMI and IgM anti-asialo GM1 titres. CONCLUSIONS: The pharyngeal-cervical-brachial variant is a clinical condition with its own clinical characteristics and well-established diagnostic criteria that allow it to be distinguished from the other variants of GBS. Our case highlights the wide clinical spectrum of acute inflammatory demyelinating polyradiculoneuropathies and the important degree of heterogeneity that exists as regards the immunological parameters.

Variante faringocervicobraquial del síndrome de Guillain-Barré: una entidad clínica bien definida con un perfil inmunológico heterogéneo / Pharyngel-cervical-brachial variant of guillain-barre syndrome: A well-defined clinical condition with a heterogeneous immunological profile

Introducción. Una variante poco frecuente del síndrome de Guillain-Barré (SGB) es la faringocervicobraquial. Dicha variante posee aspectos clínicos específicos, pero un perfil inmunológico heterogéneo. Caso clínico. Varón de 38 años de edad que presentó cuadro progresivo de disfagia, disfonía y debilidad para movilizar las extremidades superiores. Dos semanas antes, presentó un cuadro diarreico autolimitado. Mostraba paresia facial periférica bilateral de predominio derecho, y paresia de los IX y XII pares craneales y de miembros superiores (proximal 0/5, distal 1/5), sin afectación de la fuerza en miembros inferiores, sensibilidad conservada y reflejos osteotendinosos disminuidos (0 en miembros superiores y + en inferiores). A las 24 horas de ingreso sufrió deterioro respiratorio grave, que requirió traslado a la Unidad de Cuidados Intensivoscon ventilación mecánica invasiva. La electronis-tagmografía/electromiograma mostró un grave daño desmielinizante de predominio cefálico y cierto componente axonal. Inmunológicamente destacó la presencia de títulos positivos de IgG anti-GQ1b, IgM anti-GM1 e IgM anti-asialo GM1. Conclusiones. La variante faringocervicobraquial es una entidad clínica con características clínicas propias y criterios diagnósticos establecidos que permiten distinguirla de las otras variantes del SGB. Nuestro caso pone de relieve el amplio espectro clínico de las polirradiculoneuropatías desmielinizantes inflamatorias agudas y la gran heterogeneidad existente respecto a parámetros inmunológicos

Introduction. The pharyngeal-cervical-brachial variant of Guillain-Barré syndrome (GBS) is rare. This variant has its own specific clinical aspects but a heterogeneous immunological profile. Case report. A 38-year-old male who presented progressive symptoms of dysphagia, dysphonia and weakness hindering movement of the upper limbs. Two weeks earlier, the patient had presented acute self-limiting diarrhoea. He displayed predominantly right-side bilateral peripheral facial paresis, and paresis of the 9th and 12th cranial nerves and upper limbs (proximal 0/5, distal 1/5), although strength in the lower limbs was not compromised; sensitivity was preserved and deep tendon reflexes were diminished (0 in the upper limbs and + in thelower extremities). At 24 hours after admission, he suffered severe respiratory distress and had to be moved to the Intensive Care Unit with invasive mechanical ventilation. An electronystagmography/electromyogram study revealed severe demyelinating damage that predominantly involved the brain, but also included a small axonal component. The most striking immunologicalfinding was the presence of positive IgG anti-GQ1b, IgM anti-GMI and IgM anti-asialo GM1 titres. Conclusions. Thepharyngeal-cervical-brachial variant is a clinical condition with its own clinical characteristics and well-established diagnostic criteria that allow it to be distinguished from the other variants of GBS. Our case highlights the wide clinical spectrum of acute inflammatory demyelinating polyradiculoneuropathies and the important degree of heterogeneity that existsas regards the immunological parameters

El síndrome de Charles Bonnet, a propósito de un caso de 27 años / Charles Bonnet syndrome, a 27 years-old patient

El síndrome de Charles Bonnet se caracteriza por lapresencia de alucinaciones visuales complejas sin psicopatologíay sin trastornos de la conciencia. Se asociaa personas con deficiencias visuales severas bilaterales.También se ha descrito el síndrome de Charles Bonnetauditivo en pacientes con sordera adquirida. A pesar dela elevada frecuencia del trastorno, se diagnostica pocoy suele hacerse en pacientes geriátricos. Los objetivosdel presente trabajo son la revisión teórica del Síndromede Charles Bonnet y la presentación de un caso clínicode una joven de 27 años, de interés por la edad de lapaciente y porque era considerada y tratada como enfermapsiquiátrica

Charles Bonnet’s syndrome is characterized by theexistence of visual complex hallucinations without psychiatricmanifestations or cognitive disorder. Is frequentlyobserved in people with severe visual deficiency. Alsothere is an auditory Charles Bonnet’s Syndrome inpatients with deafness. Even the high frequency of thedisorder, often it isn’t correctly diagnosed, and normallyis observed in geriatric patients. In this work we present27 year old patient, she is a young patient and she wastreated like a psychiatric patient. We make a reviewabout this disease and the best indicated treatment (AU)

[Experiences with the Eurotest in neuropsychological examinations. A screening test]. / Experiencia con el Eurotest en la exploración neuropsicológica. Un test de cribado.

INTRODUCTION: The increasing number of foreign patients being attended in our health centres makes it necessary to have tests that are compatible among different countries, especially in Europe. The objective of this study is to compare the Eurotest with other screening tests and to determine whether there are any differences between European (other than Spanish) and Spanish patients. PATIENTS AND METHODS: We included patients who were referred because of complaints that were compatible with cognitive impairment and they were asked to carry out a protocol of tests that included the global deterioration scale (GDS), Folstein's MMSE (Mini-Mental State Examination), the Clock Test (CT) and the Eurotest. Epidemiological data were collected. The sample used in the study included 45 patients, 21 males and 24 females, with a mean age of 69.76 years; 34 were born in Spain and 11 abroad. RESULTS: Diagnoses were 17 with mild cognitive impairment, 8 with Alzheimer's disease, 6 with age-associated impairment, 5 with vascular dementia, 5 with a psychiatric disorder, 1 with mixed dementia and 1 with dementia with Lewy bodies. The distribution according to the GDS was as follows: 10 with a GDS of 2, 18 with a GDS of 3, and 17 with a GDS of 4. All the patients with a GDS 2 completed the tests correctly, those with a GDS 3 scored below the cut-off point 5 for the Eurotest, 4 for the MMSE and 3 for CT, and in the GDS 4 they were 9, 7 and 6, respectively. Results did not vary between Spaniards and foreigners, the kappa index between MMSE and the Eurotest was 0.39 and the Pearson coefficient was 0.67. CONCLUSION: The Eurotest was slightly more useful in patients with a greater degree of impairment.

[Mesenteric panniculitis: experience in our center]. / Paniculitis mesentérica: experiencia en nuestro centro.

Although several etiological factors have been associated with mesenteric panniculitis, the exact etiology in some cases remains unknown. Herein, we present a retrospective analysis of 8 patients affected with this disorder performed between May 2000 and December 2006. In our series the mean age at which patients presented was 63 years. The majority of the patients were male (with a male: female ratio of 3:1). The most common clinical manifestations were abdominal pain (n = 4) and asthenia (n = 4). Three cases presented with obstructive symptoms and three had a history of abdominal surgery. Notably, seven had a background of tobacco use (five smokers and two ex-smokers) and one patient developed follicular lymphoma. A literature research was carried out to analyze our results and formulate a new hypothesis. In our opinion, we believe that the study of causal factors such as tobacco and its components is required due to the strong association found in this study.

Experiencia con el Eurotest en la exploración neuropsicológica. Un test de cribado / Experiences with the eurotest in neuropsychological examinations. A screening test

Introducción. El incremento de pacientes extranjeros atendidos en nuestras consultas hace necesario disponer de tests compatibles entre múltiples países, especialmente del ámbito europeo. El objetivo del estudio es comparar el Eurotest con otros tests de cribado y comprobar si existen diferencias entre pacientes europeos (no españoles) y españoles. Pacientes y métodos. Incluimos pacientes remitidos por presentar quejas compatibles con deterioro cognitivo; se les realizó un protocolo de tests para su estudio, que incluyó la escala global de deterioro (GDS), el MMSE (Mini-Mental state examination) de Folstein, el test del reloj (TR) y el Eurotest. Recogimos datos epidemiológicos. Fueron 45 pacientes, 21 hombres y 24 mujeres, con una edad media de 69,76 años, 34 nacieron en España y 11 fuera. Resultados. Los diagnósticos fueron 17 con deterioro cognitivo leve, 8 con enfermedad de Alzheimer, 6 con deterioro asociado a la edad, 5 con demencia vascular, 5 con trastorno psiquiátrico, 1 con demencia mixta y 1 con demencia por cuerpos de Lewy. La distribución según GDS fueron: 10 con GDS de 2, 18 con GDS de 3, y 17 con GDS de 4. Todos los pacientes con GDS 2 realizaron los tests correctamente, con GDS 3 dieron por debajo del punto de corte 5 para Eurotest, 4 para MMSE y 3 para TR, y en GDS 4 fueron 9, 7 y 6, respectivamente. Los resultados no variaron entre españoles y extranjeros, el índice kappa entre MMSE y Eurotest fue de 0,39, y el coeficiente de Pearson, de 0,67. Conclusión. El Eurotest fue ligeramente más útil en pacientes más deteriorados (AU)

Introduction. The increasing number of foreign patients being attended in our health centres makes it necessary to have tests that are compatible among different countries, especially in Europe. The objective of this study is to compare the Eurotest with other screening tests and to determine whether there are any differences between European (other than Spanish) and Spanish patients. Patients and methods. We included patients who were referred because of complaints that were compatible with cognitive impairment and they were asked to carry out a protocol of tests that included the global deterioration scale (GDS), Folstein’s MMSE (Mini-Mental State Examination), the Clock Test (CT) and the Eurotest. Epidemiological data were collected. The sample used in the study included 45 patients, 21 males and 24 females, with a mean age of 69.76 years; 34 were born in Spain and 11 abroad. Results. Diagnoses were 17 with mild cognitive impairment, 8 with Alzheimer's disease, 6 with age-associated impairment, 5 with vascular dementia, 5 with a psychiatric disorder, 1 with mixed dementia and 1 with dementia with Lewy bodies. The distribution according to the GDS was as follows: 10 with a GDS of 2, 18 with a GDS of 3, and 17 with a GDS of 4. All the patients with a GDS 2 completed the tests correctly, those with a GDS 3 scored below the cutoff point 5 for the Eurotest, 4 for the MMSE and 3 for CT, and in the GDS 4 they were 9, 7 and 6, respectively. Results did not vary between Spaniards and foreigners, the kappa index between MMSE and the Eurotest was 0.39 and the Pearson coefficient was 0.67. Conclusion. The Eurotest was slightly more useful in patients with a greater degree of impairmen (AU)

Paniculitis mesentérica: experiencia en nuestro centro / Mesenteric panniculitis: experience in our center

A pesar de que se han reconocido distintos factores precipitantes en la paniculitis mesentérica, su etiología en determinados casos es incierta. Presentamos un análisis retrospectivo de 8 pacientes afectados de paniculitis mesentérica en un periodo comprendido entre mayo 2000 hasta diciembre 2006. En nuestra serie la edad media de presentación fue 63 años, siendo la mayoría de pacientes varones (proporción 3:1). Las manifestaciones clínicas más frecuentes fueron el dolor abdominal (n = 4) y la astenia (n = 4). Tres casos se presentaron como cuadro de obstrucción y tres casos presentaron antecedentes de cirugía abdominal. El antecedente más común fue el tabaquismo (5 casos eran fumadores activos y 2 exfumadores) y hubo un paciente que desarrolló un linfoma folicular en el seguimiento. Revisamos la literatura para analizar nuestros resultados y formular una hipótesis. En nuestra opinión, pensamos que debe ser analizada de forma más exhaustiva la relación entre el tabaco y sus componentes con la aparición de la enfermedad debido a la fuerte asociación encontrada en este estudio

Although several etiological factors have been associated with mesenteric panniculitis, the exact etiology in some cases remains unknown. Herein, we present a retrospective analysis of 8 patients affected with this disorder performed between May 2000 and December 2006. In our series the mean age at which patients presented was 63 years. The majority of the patients were male (with a male: female ratio of 3:1). The most common clinical manifestations were abdominal pain (n = 4) and asthenia (n = 4). Three cases presented with obstructive symptoms and three had a history of abdominal surgery. Notably, seven had a background of tobacco use (five smokers and two ex-smokers) and one patient developed follicular lymphoma. A literature research was carried out to analyze our results and formulate a new hypothesis. In our opinion, we believe that the study of causal factors such as tobacco and its components is required due to the strong association found in this study

Infarto migrañoso y citrato de clomifeno / Migrainous infarction and clomiphene citrate

No disponible

No disponible

Trombosis venosa cerebral y enfermedad inflamatoria intestinal / Cerebral venous thrombosis and inflammatory bowel disease

No disponible

No disponible

Pseudoartrosis del húmero / Nonunions of the humerus

Objetivo: Evaluación del manejo y resultados de los casos de pseudoartrosis de diáfisis húmeral tratados quirúrgicamente entre febrero de 1992 y diciembre de 2001. Pacientes y Métodos: Estudio restrospectivo de 18 casos, 15 hombres (83,3 por ciento) y 3 mujeres (16,7 por ciento), con una edad promedio de 39,6 años y un seguimiento promedio de 68,3 meses. Siete casos presentaron una pseudoartrosis atrófica (38,9 por ciento) y en 6 casos fue hipertrófica (33,3 por ciento) y en 5 casos hipotrófica (27,8 por ciento). Todos los casos fueron tratados quirúrgicamente, empleando fijación interna con placa en 12 casos (66,7 por ciento) y enclavado endomedular en 6 casos (33,3 por ciento). En 12 casos se efectuó aporte de injerto óseo (66,7 por ciento). Resultados: La consolidación se obtuvo en promedio a las 12,7 semanas luego del tratamiento quirúrgico de la pseudoartrosis, con un rango entre 8 y 24 semanas. La valoración funcional fue buena en pseudoartrosis, con una rango entre 8 y 24 semanas. La valoración funcional fue buena en 17 casos (94,4 por ciento) y defieciente en 1 caso (5,6 por ciento). Hubo dos complicaciones que fueron 1 caso de hematoma de herida operatoria y 1 caso de infección superficial en la cresta ilíaca donante (11,1 por ciento). Conclusión: La pseudoartrosis de la diáfisis humeral requiere habitualmente de tratamiento quirúrgico, siendo la fijación más aporte de injerto óseo el método de elección para las lesiones atróficas e hipotróficas y la correcta estabilización en el tratamiento de las lesiones hipertróficas.

FKBP binding characteristics of cardiac microsomes from diverse vertebrates.

FK506 binding protein (FKBP) is a cytosolic receptor for the immunosuppressive drug FK-506. The common isoform, FKBP12, was found to be associated with the calcium release channel (ryanodine receptor 1) of different species of vertebrate skeletal muscle, whereas 12.6, a novel FKBP isoform was found to be associated with canine cardiac ryanodine receptor (ryanodine receptor 2). Until recently, canine cardiac sarcoplasmic reticulum was considered to be the prototype for studying heart RyR2 and its interactions with FKBP. In this study, cardiac microsomes were isolated from diverse vertebrates: human, rabbit, rat, mice, dog, chicken, frog, and fish and were analyzed for their ability to bind or exchange with FKBP isoforms 12 and 12.6. Our studies indicate that RyR2 from seven out of the eight animals contain both FKBP12 and 12.6. Dog is the exception. It can now be concluded that the association of FKBP isoforms with RyR2 is widely conserved in the hearts of different species of vertebrates.